STL Index for: Finasteride

Hidradenitis Suppurativa: A Review with a Focus on Treatment Data

Hidradenitis suppurativa (HS) is a chronic disease of the follicular unit that often leads to marked impairment of quality of life. This article reviews various treatment modalities for HS including laser, surgery, retinoids, immunosuppression, biologics, and antibiotics.

Promising Therapies for Treating and/or Preventing Androgenic Alopecia

Androgenetic alopecia (AGA) may affect up to 70% of men and 40% of women at some point in their lifetime. Here we briefly review current therapeutic options and treatments under active investigation.

Update on Drugs and Drug News: May 2012

Update on drugs, approval dates, and comments. Belimumab Adapalene (0.3% gel Differin®), Vemurafenib tablet (Zelboraf®), Wound care spray (Granulox®), as well as devices like the laser device for onychomycosis Harmony® XL are covered.

Polycystic Ovary Syndrome and Acne

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in reproductive aged women. This article will review the treatments for acne due to androgen excess in PCOS women.

Management of Hirsutism

Hirsutism is a relatively common condition affecting about 5%-10% of women of childbearing age. Herein, we present an overview of hirsutism with emphasis on its etiology and therapeutic options.

Finasteride for Male Pattern Hair Loss

Finasteride 1 mg (Propecia®, Merck) was approved by the US FDA December, 1997 for the treatment of male pattern hair loss (androgenetic alopecia, AGA) in men only. Safety and efficacy were demonstrated in men between 18 and 41 years of age with mild to moderate hair loss of the vertex and anterior mid-scalp area.